Smoking is a major global public health challenge with serious health consequences and is the leading cause of preventable disease and death in both developed and developing countries ([@R30]). Of \>7000 components of tobacco smoke, nicotine is most associated with tobacco addiction ([@R4]; [@R29]). In 2013, 21% of adults globally were current smokers and the total number of global tobacco users was 1.1 billion ([@R32]). China has become the world\'s largest center for tobacco consumption, accounting for one-third of the world\'s tobacco users. In the 2015 China Adult Tobacco Survey (CATS), smoking prevalence among Chinese people aged 15 years and over was reported at 27.7%, representing 316 million smokers ([@R23]). In 2005, an estimated 0.67 million deaths in Chinese adults aged over 40 years were attributable to smoking ([@R11]). It is predicted that smoking-related mortality for China will rise to more than 2 million people per year by 2030 ([@R2]).

Male smokers predominate in China ([@R36]). In the 2015 GATS, reported smoking prevalence among Chinese men was 52.1% versus 2.7% among women ([@R23]). Smoking prevalence is also higher in men in Western countries, but the gender gap is far less compared with China ([@R9]). According to the 2010 GATS report, only 16.9% of ever smokers in China had quit smoking and most quit attempts occurred without use of cessation aids ([@R2]).

Current first-line pharmacological alternatives for smoking cessation include nicotine replacement therapy (NRT), bupropion (antidepressant, not targeting nicotine), and varenicline (selective partial nicotine receptor agonist) ([@R33]; [@R17]). NRT was developed the earliest (1970s), has established efficacy and safety ([@R27]; [@R17]), and remains one of the most popular and recommended therapies for smoking cessation ([@R27]; [@R10]; [@R15]). NRT is available in a number of different formulations, including chewing gum, transdermal patch, inhalers, nasal or oral spray, and lozenge to accommodate individual preference or medical circumstance (eg, temporomandibular joint pain, odontopathy). NRTs contain about 50% of the nicotine dose obtained from smoking, providing some relief of withdrawal symptoms to help the smoker quit completely ([@R4]).

The pharmacologic treatment of nicotine addiction is a relatively new concept in China, from both the patient and the healthcare provider perspective ([@R13]; [@R34]). Although NRT has been investigated in Chinese smokers from Hong Kong ([@R21]) and Taiwan ([@R14]), data on NRT effectiveness in mainland Chinese smokers are few ([@R34]). Given the pervasiveness of tobacco use in China and its associated harms, more research is needed to assess the effectiveness of pharmacologic options that facilitate smoking cessation in this population.

Toward that end, this article details a phase 3 clinical study evaluating the effectiveness of NRT in adult Chinese smokers who are motivated to quit. The primary objective was to demonstrate the efficacy of 2 and 4 mg nicotine mint lozenges in smoking cessation, defined as continuous abstinence for the 28-day period up to and including the visit at week 6. Secondary objectives included assessment of continuous cessation rates at week 12 and week 24; long-term smoking cessation rate at week 24; 7-day point-prevalence cessation rates at weeks 1, 2, 4, 6, 12, and 24; relief of nicotine craving and withdrawal symptoms associated with cessation; body weight change from baseline to weeks 6, 12, and 24; electrocardiogram (ECG), vital signs, laboratory, and adverse events (AEs).

METHODS
=======

Study Design
------------

This was a multicenter, randomized, stratified (low- and high-dependence smoking status), double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov registration: NCT00985985) to evaluate the efficacy and safety of 2 and 4 mg nicotine mint lozenges in Chinese adult smokers during a 12-month period of smoking cessation.

Study Sites and Ethics Approval
-------------------------------

The study was conducted at 10 academic or hospital-associated smoking cessation clinics in 6 cities (Beijing, Shenyang, Tianjin, and Shanghai \[2 sites each\]; Hangzhou and Guangzhou \[1 site each\]) in China between May 8, 2009, and February 9, 2011. Study participants were recruited from smoking cessation clinics and via advertisements published in the hospitals. The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and its amendments, International Conference on Harmonisation Guideline for Good Clinical Practice, and other applicable regulations. The study protocol, protocol amendments, and subject-informed consent form were reviewed and approved by the Ethics Committees of all 10 investigational sites and by the China Food and Drug Administration. All subjects provided written informed consent prior to participation in this study.

Study Procedure
---------------

Subject demographics, past medical history, vital signs, physical examinations, laboratory (including pregnancy) tests, ECGs, concomitant medications, baseline CO levels, smoking history questionnaires, and diary cards were completed and recorded during screening.

This 12-month study had a maximum of 13 visits, which included both outpatient visits and telephone visits. A complete schedule of study procedures by visit can be found in Supplementary Table 1. Visit 1 was for screening and recording of subjects' baseline characteristics and medical history. At visit 2 (the subject\'s designated target smoking quit date), subjects were stratified by nicotine dependence level (see below) and randomized to NRT or placebo; a User\'s Guide for smoking cessation using nicotine lozenges was provided. Body weight, concomitant medications, and vital signs were recorded. Subjects received low-intensity behavioral support (10 minutes) beginning at visit 2 through visit 5 (ie, Weeks 0, 1, 2, and 4 of treatment). Subjects were considered treatment failures if they had either an expiratory CO level greater than 10 ppm or reported smoking between visit 5 (4 weeks postquit ± 3 days) and visit 13 (12 months postquit ± 5 days). Investigators followed up with subjects who reported no more than 6 days of smoking at week 24 (visit 10) by telephone during visit 11 (8 months postquit ± 5 days), visit 12 (10 months postquit ± 5 days), and visit 13 (12 months postquit ± 5 days).

All study treatments were provided by Sino-American Tianjin Smith Kline & French Laboratories Ltd, Tianjin, China. The study treatments were administered buccally for absorption through the oral mucosa. Lozenges were moved from side to side in the mouth until completely dissolved and were not to be chewed or swallowed. The dose schedule was split into stages (Supplementary Table 2). Diary cards were provided to record cravings, withdrawal symptoms, and daily lozenge usage.

Randomization, Sample Size, and Blinding
----------------------------------------

Subjects were stratified into high-dependence and low-dependence strata based on "time to first cigarette" given that previous investigations of individual items from the Fagerström Test for Nicotine Dependence (FTND) have shown that this item provided the strongest predictor of early (1 week) and late (6 month) quitting success ([@R3]). The high-dependence stratum, consisting of subjects who smoked their first cigarette within 30 minutes of awakening, were randomized to receive either the 4 mg nicotine lozenge or matching 0 mg nicotine placebo lozenge. The low-dependence stratum, consisting of subjects who smoked their first cigarette \>30 minutes after awakening, were randomized to receive either the 2 mg nicotine lozenge or matching 0 mg nicotine placebo lozenge. The randomization schedule was computer-generated and was provided to the site by the GSK Biostatistics Department.

The sample size for the 2 mg stratum was calculated by assuming 6-week cessation rates of 46% for active nicotine versus 30% for placebo lozenge. To obtain 90% power for detection of a significant difference at the 2-sided 5% significance level, 200 subjects per group were required, so an enrollment target of 480 participants was used. The sample size for the 4 mg stratum was calculated by assuming 6-week cessation rates of 49% for active nicotine versus 30% for placebo lozenge. To obtain 90% power for detection of a significant difference at the 2-sided 5% significance level, 65 subjects per group were required. However, to meet the recommendation of the regulatory body, China Food and Drug Administration, 120 subjects per group were recruited.

This was a double-blind study. Sponsors, sponsor\'s representatives, the investigator, staff, and subjects were blinded to treatment regimen.

Inclusion and Exclusion Criteria
--------------------------------

The study included Chinese adult smokers (≥18 years old who smoked daily for at least 1 year before study enrollment) who had a strong motivation to quit smoking as assessed by an affirmative response to the question "Are you motivated to quit smoking within the next 30 days using NRT or placebo lozenges?" and the investigator\'s clinical opinion. The subjects' smoking histories were recorded, including FTND scores, time to first cigarette, difficulty refraining from smoking, number of cigarettes smoked per day, smoking during illness, and other variables. Subjects had to be capable of understanding instructions and providing written informed consent.

Subjects were excluded if they used tobacco other than cigarettes (eg, pipes, cigars, snuff) or nicotine delivery systems other than lozenge (eg, nicotine gum, nicotine patch, nicotine inhaler, or nasal spray); smoked illicit substances (eg, cannabis, cocaine, heroin, ice drug); used smoking cessation aids within 30 days before study entry; had a history of alcohol or drug use; were currently involved in any other clinical trial or previous participation in this study; were pregnant, breastfeeding, or of childbearing potential but refused use of medical contraception; had unstable or uncontrolled systemic medical conditions, hyperthyroidism, or used insulin for diabetes mellitus; recent myocardial infarction or cerebral vascular accidents; allergy to aspartame or phenylpyruvic acid; diagnosis of phenylketonuria; or medical history endangering subject safety or study result validity.

Study Parameter Measurements
----------------------------

The study subjects made 8 in-person outpatient visits to the study site through 24 weeks. Outpatient visits occurred at screening and weeks 0, 1, 2, 4, 6, 12, and 24 after initiation of treatment. In addition, subjects underwent 5 telephone visits with study investigators at 16 and 20 weeks, and at 8, 10, and 12 months. The measurements and procedures conducted at each visit are summarized in Supplementary Table 1.

The primary efficacy endpoint was 28-day continuous smoking abstinence at 6 weeks. This endpoint was selected because previous studies indicate that early quitting success may be a predictor of long-term quitting success ([@R16]; [@R19]; [@R1]). Abstinence was confirmed by expiratory CO levels threshold of ≤10 ppm at each in-person visit to the study site (Supplementary Table 1). This cutoff was chosen because this threshold was used in a previous trial of the 2 and 4 mg lozenges and has been recommended for use in clinical trials ([@R26]; [@R28]). Subjects who failed to meet the success criteria and those with unknown smoking status were counted as failures.

Secondary efficacy parameters were point prevalence of abstinence at time points through week 24, defined as complete abstinence from smoking for the 7 days up to and including the evaluation day; long-term successful cessation at week 24 (defined as meeting the 6-week success criteria and subsequently smoking on ≤6 days between weeks 6 and 24); relief of craving/total withdrawal symptoms; and changes in body weight. The safety parameters were PE, vital signs, laboratory tests, ECG, and AEs.

Statistical Analysis
--------------------

Efficacy and safety statistical analyses were performed separately for the 2 and 4 mg strata. Three analysis populations were defined: full analysis set (FAS; all randomized subjects except those known not to have taken any study medication) for the primary analysis, per-protocol set (PPS; subjects in good compliance with study protocol), and safety set (SS; all randomized subjects having taken at least 1 dose of study medication).

All smoking cessation rates were compared using a Cochran-Mantel-Haenszel test with adjustment for center effect. The relief of craving/withdrawal symptoms was analyzed by a Wilcoxon rank sum test to compare nicotine with placebo (separately within each stratum). Change in body weight among subjects who quit was analyzed with an analysis of covariance model that included effects of treatment, dosing amount, baseline body weight, response, and center (separate analysis within each stratum). All statistical tests were 2-sided at the 5% significance level. Safety analysis consisted of tabulation of AEs.

A post hoc efficacy analysis was conducted on the continuous abstinence endpoints at 6, 12, and 24 weeks in subpopulations of the FAS based on various baseline characteristics including total FTND score (\<6 or ≥6), number of prior quit attempts (\<2 or ≥2), number of cigarettes per day (≥10, \<20, and ≥20), and average lozenge use over the first 6 weeks (\<9/day or ≥9 per day) and were compared using a Cochran-Mantel-Haenszel test.

RESULTS
=======

Disposition of Subjects
-----------------------

A total of 781 subjects were screened; 58 failed to meet the inclusion/exclusion criteria and therefore 723 subjects were randomized and comprised the FAS, including 240 high-dependence and 483 low-dependence smokers. The disposition of subjects in the FAS analysis is provided in Supplementary Figure 1. Discontinuation rates were similar between treatment groups in each stratum. The most common reasons for discontinuation were "other" (n = 6) and lost to follow-up (n = 5) in the high-dependence stratum and lost to follow-up (n = 15) and lack of efficacy (n = 11) in the low-dependence stratum. The PPS included a total of 688 subjects. There were 459 subjects (227 nicotine and 232 placebo) in the 2 mg stratum and 229 subjects (115 nicotine and 114 placebo) in the 4 mg stratum. The SS included 720 subjects and included all 483 subjects (241 nicotine and 242 placebo) randomized to the 2 mg stratum and 237 subjects (119 nicotine and 118 placebo) randomized to the 4 mg stratum. Three subjects were excluded from the SS because of nonuse of study drug.

Demographics and Other Baseline Characteristics
-----------------------------------------------

The 2 mg stratum enrolled 465 (96.27%) male and 18 (3.73%) female subjects. Baseline age was 39.1 ± 11.78 years; height, 171.6 ± 5.72 cm; body weight, 72.1 ± 11.23 kg. In the 4 mg stratum, subjects were 234 (97.91%) male and 5 (2.09%) female; age, 42.2 ± 10.45 years; height, 172.6 ± 5.73 cm; body weight, 75.1 ± 11.9 kg. All subjects showed tobacco dependence. Both strata had more than 50% of subjects smoking 11--20 cigarettes daily, and greater than 50% of subjects had previously tried to quit smoking without success (Supplementary Table 3).

Primary Efficacy Analysis
-------------------------

In the FAS, the primary analysis showed higher week 6 smoking cessation rates for the nicotine mint lozenge compared with placebo in both strata. However, only the 4 mg stratum approached statistical significance (*P* = 0.0565). In the low-dependence (2 mg) stratum, 59 subjects (24.48%) of 241 in the active nicotine group and 52 subjects (21.49%) of 242 in the placebo group were successful quitters (*P* *=* .3851). In the high-dependence (4 mg) stratum, 37/120 subjects (30.83%) in the active nicotine group and 24/119 subjects (20.17%) in the placebo group were successful quitters (*P* = .0565) (Table [1](#T1){ref-type="table"}).

###### 

Analysis of Successful Smoking Cessation Rate at Week 6 (Primary Efficacy; Full Analysis Set)

                                                 Low-dependence Stratum (2 mg)   High-dependence Stratum (4 mg)                                           
  ---------------------------------------------- ------------------------------- -------------------------------- ------------- ------------ ------------ -------------
  N                                              241                             242                              483           120          119          239
  Failed, n (%)                                  182 (75.52)                     190 (78.51)                      372 (77.02)   83 (69.17)   95 (79.83)   178 (74.48)
  Succeeded, n (%)                               59 (24.48)                      52 (21.49)                       111 (22.98)   37 (30.83)   24 (20.17)   61 (25.52)
  *P* value[^\*^](#TF1-1){ref-type="table-fn"}   0.3851                                                                         0.0565                    
  OR[^\*^](#TF1-1){ref-type="table-fn"}          1.22                                                                           1.82                      
  95% CI                                         0.78--1.92                                                                     0.99--3.32                

^\*^*P* value based on Cochran-Mantel-Haenszel test (adjusted by center); OR based on logistic model (adjusted by center).

CI, confidence interval; NRT, nicotine replacement therapy; OR, odds ratio.

Secondary Efficacy Analysis
---------------------------

The week 6 quit rates in the PPS was a secondary efficacy measure (Fig. [1](#F1){ref-type="fig"}) that was analyzed using the same method as the primary analysis. Results were consistent with the primary FAS results.

![Continuous abstinence rate at week 6 in per-protocol set (secondary efficacy parameter). CAR, continuous abstinence rate.](adm-14-69-g001){#F1}

There were no significant between-treatment differences (nicotine vs placebo) in the 2 mg stratum for the rate of continuous successful smoking cessation in subjects from the FAS at week 12, week 24, and month 12 (all *P* values \>0.05; Table [2](#T2){ref-type="table"} and Fig. [2](#F2){ref-type="fig"}). However, in the 4 mg stratum, significantly more subjects in the nicotine lozenge group quit smoking continuously and successfully versus placebo at week 12 (22.5% vs 10.9%; OR: 2.46; 95% CI: 1.18--5.10; *P* = 0.0160) and week 24 (19.2% vs 10.1%; OR: 2.18; 95% CI: 1.02--4.67; *P* = 0.0464), although there was no significant difference between treatments at month 12 (15.8% vs 9.2%; OR: 1.85; 95% CI: 0.84, 4.07; *P* = 0.1226). Results of the PPS analysis were consistent with those of the FAS.

###### 

Secondary Efficacy Endpoints (Full Analysis Set)

                                                                                              Low-dependence Stratum (2 mg)                  High-dependence Stratum (4 mg)                                            
  ------------------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------- ---------------------------------------- ------------
  Continuous successful smoking cessation[^\*^](#TF2-1){ref-type="table-fn"}                                                                                                                                           
   Week 12                                                                                                                                                                                                             
    Failed, n (%)                                                                             198 (82.2)                                     201 (83.1)                       93 (77.5)                                106 (89.1)
    Succeeded, n (%)                                                                          43 (17.8)                                      41 (16.9)                        27 (22.5)                                13 (10.9)
    *P* value[^†^](#TF2-2){ref-type="table-fn"}                                               0.740                                                                           0.016                                    
    OR[^†^](#TF2-2){ref-type="table-fn"}                                                      1.09                                                                            2.46                                     
    95% CI                                                                                    0.66--1.78                                                                      1.18--5.10                               
   Week 24                                                                                                                                                                                                             
    Failed, n (%)                                                                             210 (87.1)                                     210 (86.8)                       97 (80.8)                                107 (89.9)
    Succeeded, n (%)                                                                          31 (12.9)                                      32 (13.2)                        23 (19.2)                                12 (10.1)
    *P* value[^†^](#TF2-2){ref-type="table-fn"}                                               0.951                                                                           0.046                                    
    OR[^†^](#TF2-2){ref-type="table-fn"}                                                      0.98                                                                            2.18                                     
    95% CI                                                                                    0.56--1.72                                                                      1.02--4.67                               
   Month 12                                                                                                                                                                                                            
    Failed, n (%)                                                                             215 (89.2)                                     214 (88.4)                       101 (84.2)                               108 (90.8)
    Succeeded, n (%)                                                                          26 (10.8)                                      28 (11.6)                        19 (15.8)                                11 (9.2)
    *P* value[^†^](#TF2-2){ref-type="table-fn"}                                               0.822                                                                           0.123                                    
    OR[^†^](#TF2-2){ref-type="table-fn"}                                                      0.93                                                                            1.85                                     
    95% CI                                                                                    0.51--1.69                                                                      0.84--4.07                               
  Long-term successful smoking cessation rates at week 24[^†^](#TF2-2){ref-type="table-fn"}                                                                                                                            
   Failed, n (%)                                                                              195 (80.9)                                     199 (82.2)                       91 (75.8)                                100 (84.0)
   Succeeded, n (%)                                                                           46 (19.1)                                      43 (17.8)                        29 (24.2)                                19 (16.0)
   *P* value[^†^](#TF2-2){ref-type="table-fn"}                                                0.648                                                                           0.111                                    
   OR[^†^](#TF2-2){ref-type="table-fn"}                                                       1.12                                                                            1.72                                     
   95% CI                                                                                     0.69--1.82                                                                      0.89--3.32                               
  7-Day point prevalence abstinence (%)                                                                                                                                                                                
   Week 1                                                                                     12.5                                           12.0                             20.0[^§^](#TF2-4){ref-type="table-fn"}   10.1
   Week 2                                                                                     21.2                                           23.1                             33.3                                     26.1
   Week 4                                                                                     32.0                                           26.3                             36.7                                     30.3
   Week 6                                                                                     35.7                                           37.2                             41.7                                     32.8
   Week 12                                                                                    41.5                                           39.3                             40.8[^§^](#TF2-4){ref-type="table-fn"}   26.1
   Week 24                                                                                    41.5                                           43.1                             50.0                                     43.7
  Relief of craving/withdrawal symptoms, total scores (successful quitters)                                                                                                                                            
   Week 1                                                                                     7.42                                           6.14                             5.89                                     9.20
   Week 2                                                                                     6.42                                           4.67                             5.07                                     8.02
   Week 4                                                                                     4.52                                           4.18                             3.01                                     7.33
   Week 6                                                                                     4.09                                           3.71                             3.13                                     6.56
  Change from baseline in body weight (successful quitters), kg (SD)                                                                                                                                                   
   Week 6                                                                                     1.5 (1.76)                                     1.3 (2.45)                       1.7 (2.93)                               1.5 (1.76)
   Week 12                                                                                    1.9 (2.24)                                     1.8 (2.43)                       1.8 (2.94)                               1.8 (2.22)
   Week 24                                                                                    2.0 (2.75)[^§^](#TF2-4){ref-type="table-fn"}   1.2 (2.56)                       2.4 (4.05)                               2.8 (2.80)

^\*^Proportion of subjects who achieved the primary endpoint at week 6 and quit smoking completely by week 12 and week 24.

^†^*P* value based on Cochran-Mantel-Haenszel test (adjusted by center); OR based on logistic model (adjusted by center).

^‡^Proportion of subjects who achieved the primary endpoint with no more than 6 cumulative days of smoking from week 6 to week 24.

^§^*P* \< 0.05.

CI, confidence interval; NRT, nicotine replacement therapy; OR, odds ratio.

![Continuous abstinence rate in full analysis set over time. ^∗^*P* \< 0.05 versus corresponding placebo based on Cochran--Mantel--Haenszel test (adjusted by center). CAR, continuous abstinence rate.](adm-14-69-g002){#F2}

Nicotine mint lozenge provided higher rates of long-term successful smoking cessation versus placebo (Table [2](#T2){ref-type="table"}) at week 24 in both the 4 and 2 mg strata of the FAS (4 mg, 24.17% vs placebo, 15.97%; 2 mg, 19.09% vs placebo, 17.77%), but without statistical significance (4 mg, OR: 1.72; 95% CI: 0.89--3.32; *P* = 0.1105; 2 mg, OR: 1.12; 95% CI: 0.69--1.82; *P* = 0.6484). Results of the PPS analysis were consistent with those of FAS.

In the FAS, the 7-day point-prevalence success rates (Table [2](#T2){ref-type="table"}) increased over time from week 1 to week 24 in both the 4 and 2 mg strata and in both the nicotine and placebo treatment groups. Week 24 success rates were 1.5--3.0 times those of week 1. In the 2 mg stratum, treatment differences between nicotine and placebo were not statistically significant. In the 4 mg stratum, nicotine lozenge provided significantly higher success rates than placebo at week 1 (20% vs 10.1%; *P* = 0.0233) and week 12 (40.83% vs 26.05%; *P* = 0.0159). PPS analysis results were consistent with those of FAS.

Nicotine Cravings and Withdrawal Symptoms
-----------------------------------------

Nicotine craving and withdrawal symptoms were evaluated daily with the Minnesota Nicotine Withdrawal Scale (MNWS). MNWS scores for craving/withdrawal symptoms in both strata declined gradually during the first 6 weeks (Table [2](#T2){ref-type="table"}). There were no significant differences in MNWS scores between the 2 mg nicotine lozenge group and the 2 mg placebo groups at any time point. The 4 mg nicotine lozenge provided significantly higher rates of continuous abstinence versus 4 mg placebo at weeks 1 (20% vs 10.1%; *P* = 0.023) and 12 (40.8% vs 26.1%; *P* = 0.016). In the subpopulation of successful quitters only, however, the total MNWS scores in the nicotine group were significantly lower than those in the placebo group at weeks 3, 4, 5, and 6 for the 4 mg stratum (Table [2](#T2){ref-type="table"}).

Weight Gain
-----------

Weight gain may accompany smoking cessation; therefore, the most meaningful comparison of weight gain between nicotine and placebo lozenge in both strata is in the subpopulation of successful smoking quitters. In that population, there was no significant difference in weight gain at any time point except in the 2 mg stratum at 24 weeks (nicotine, 2.0 kg vs placebo, 1.2 kg, *P* = 0.0497) (Table [2](#T2){ref-type="table"}).

Safety Analysis
---------------

### Adverse Events

Table [3](#T3){ref-type="table"} summarizes AE rates by preferred terms according to the Medical Dictionary for Regulatory Activities. AEs were more frequent with active nicotine lozenges than with placebo; most AEs were mild or moderate in severity. In the 2 mg nicotine group, a total of 219 AEs occurred in 111 subjects (46.1%); 1 event (0.4%) was definitely related to the study drug, 19 (7.9%) were probably related to study drug, and 28 (11.6%) were possibly related to study drug. In the 4 mg nicotine group, 129 AEs occurred in 61 (51.3%) subjects; 4 events (3.4%) were definitely related to study drug, 11 (9.2%) were probably related to study drug, and 16 (13.5%) were possibly related to study drug. The most common AEs encountered were upper respiratory tract infections, nasopharyngitis, and nausea; all are known side effects of NRT. A total of 8 subjects discontinued treatment because of AEs: 3 in the 2 mg nicotine group (1.2%), 2 in the 2 mg placebo group (0.8%), 1 in the 4 mg nicotine group (0.8%), and 2 in the 4 mg placebo group (1.7%).

###### 

Adverse Events by Preferred Term

                             Low-dependence Stratum (2 mg)   High-dependence Stratum (4 mg)               
  -------------------------- ------------------------------- -------------------------------- ----------- -----------
  Any AE                     111 (46.1)                      91 (37.6)                        61 (51.3)   58 (49.2)
  URTI                       27 (11.2)                       19 (7.9)                         17 (14.3)   11 (9.3)
  Nasopharyngitis            16 (6.6)                        14 (5.8)                         13 (10.9)   5 (4.2)
  Nausea                     15 (6.2)                        10 (4.1)                         7 (5.9)     8 (6.8)
  Diarrhea                   9 (3.7)                         9 (3.7)                          2 (1.7)     2 (1.7)
  Abdominal distension       6 (2.5)                         2 (0.8)                          1 (0.8)     3 (2.5)
  Oropharyngeal discomfort   7 (2.9)                         0                                0           0
  Vomiting                   5 (2.1)                         0                                0           1 (0.9)
  Dizziness                  10 (4.2)                        0                                3 (2.5)     4 (3.4)
  Palpitations               5 (2.1)                         1 (0.4)                          3 (2.5)     2 (1.7)
  Hypertension               5 (2.1)                         0                                0           2 (1.7)
  Somnolence                 0                               0                                3 (2.5)     0
  Insomnia                   1 (0.4)                         0                                3 (2.5)     2 (1.7)
  Dyspnea                    1 (0.4)                         2 (0.8)                          6 (5.0)     2 (1.7)

AE, adverse event; URTI, upper respiratory tract infection.

Three subjects experienced 5 serious AEs (SAEs). One subject in the 4 mg placebo arm had 3 SAEs (bile duct stone, biliary tract infection, and cholelithiasis) that were considered by the investigator as irrelevant to the study drug. One subject in the 2 mg nicotine group had 1 SAE (acute onset of cough and expectoration in a patient with underlying chronic obstructive pulmonary disease) and 1 subject in the 4 mg active nicotine arm had 1 SAE (skin laceration); the 2 SAEs were assessed by the investigator as possibly irrelevant and irrelevant, respectively, to the study drug. No deaths or disabilities were reported. All 3 subjects with SAEs fully recovered. In the 2 mg nicotine group, 6 subjects (2.5%) had increased blood pressure and 2 subjects (0.8%) had increased blood glucose. Also, the blood glucose of 2 subjects (1.7%) increased in the 4 mg nicotine group. During the study, no other clinically relevant AEs were noted in terms of changes in vital signs, physical exam status, or laboratory tests.

Post Hoc Efficacy Analysis
--------------------------

A post hoc efficacy analysis was conducted on the continuous abstinence endpoints at 6, 12, and 24 weeks in subpopulations of the FAS, according to 3 baseline characteristics: nicotine dependency (FTND \<6, FTND ≥6), number of previous smoking quit attempts (\<2, ≥2), and number of cigarettes smoked per day at baseline (\>10, ≤20, \>20); the 2 and 4 mg strata were analyzed separately. Results were similar to those of the entire FAS except for the subsets with prior quit attempts. In those with fewer than 2 prior quit attempts (approximately two-thirds of FAS subjects), the 2 mg stratum had higher quit rates with placebo. In the subset with 2 or more prior quit attempts (approximately one-third of FAS subjects), the 2 mg stratum had a significantly higher quit rate with nicotine than placebo at all 3 time points (*P* = 0.0009 at week 6, *P* = 0.0133 at week 12, *P* = 0.0039 at week 24).

DISCUSSION
==========

The primary efficacy parameter in this study was 28-day continuous successful smoking quit rate at the end of week 6. In the 2 mg stratum, the success rates were 24.48% for nicotine versus 21.49% for placebo, which was similar between groups and did not reach statistical significance (OR: 1.22; 95% CI: 0.78--1.92; *P* = 0.3851). In the 4 mg stratum, the success rate of 30.8% for nicotine versus 20.2% for placebo approached statistical significance (OR: 1.82; 95% CI: 0.99--3.32; *P* = 0.0565).

The low-intensity behavioral support employed in this study may help explain why the efficacy of NRT appeared lower than expected in this population. Behavioral support is an important component of smoking cessation efforts with NRT in the real world, and such support has been shown to have a significant positive effect on the efficacy of NRT and other cessation therapies ([@R20]; [@R22]). Only minimal behavioral support was offered as part of this study in order to avoid confounding the effects of the treatment, but this lack of additional support may have reduced the observed effects of NRT.

The results of the current study, and the efficacy of smoking cessation therapies in general, have significant implications for efforts to reduce rates of smoking in China. The push to reduce smoking in China is not as well established as cessation campaigns in the US and Europe. The availability of NRT is low and medication use for smoking cessation has been reported to be less than 6% among smokers ([@R35]; [@R18]), so the need for effective pharmacotherapeutic options for nicotine dependence is great in this population.

Few smoking cessation studies in mainland Chinese subjects can be used for comparison. An open-label, multicenter clinical study tested the effectiveness of 12 weeks of NRT treatment (including a 12-week off-treatment follow-up) provided as either nicotine gum (2 or 4 mg) or nicotine patches in 300 Chinese physicians from 6 general hospitals in Beijing, Shanghai, and Guangzhou who were motivated to quit smoking ([@R34]). Enrolled patients smoked at least 10 cigarettes per day for at least 3 years; only 2% had previously used any type of stop-smoking medication. Continuous abstinence from weeks 2 to 24 occurred in 17% of subjects overall and was the highest in subjects treated with 2 mg nicotine gum (20.9%). The point-prevalence abstinence rate at week 24 was 35%; 38% had reduced daily cigarette consumption by 50% ([@R34]). Although the 2 mg nicotine lozenge provided no significant benefit versus placebo in rate of successful smoking cessation at 12 or 24 weeks in our study, this was not the case with the 4 mg nicotine lozenge, where the odds of successful abstinence at 12 and 24 weeks was more than 2-fold that found with placebo treatment.

Nicotine sublingual tablets were investigated in a randomized, double-blind, placebo-controlled, 3-month smoking cessation trial in adult smokers who smoked at least 10 cigarettes per day for at least 1 year from communities in Beijing, China ([@R12]). The primary study outcome was self-reported abstinence rates at 2 and 3 months. At the end of 3 months, 52.2% of subjects taking nicotine sublingual tablets reported abstinence at 3 months versus 19.1% taking placebo. A 50% reduction in smoking was found in 42.6% on NRT versus 14.8% on placebo ([@R12]).

Smokers' demographic and baseline characteristics, as well as NRT option and use, have been shown in previous clinical studies to influence smoking cessation ([@R25]; [@R31]; [@R8]; [@R6]). It is speculated that a good statistical design and analysis model (eg, the adjusted multivariate logistic regression model) adjusted and controlled for as many key demographic and baseline characteristics as possible might produce a clinical outcome more tailored to Chinese smokers.

LIMITATIONS
===========

The use of CO measurements to confirm smoking status is an important limitation to this study. The 10 ppm threshold used to identify smoking relapse has been recommended and utilized in past studies of NRT, but more recently, concerns that this threshold misclassifies too many smokers as abstainers has led to lower thresholds (3--4 ppm) being recommended and used ([@R24]; [@R7]). Additionally, exhaled CO has a half-life of 2--8 hours ([@R28]) and is an indicator of acute smoking only. Consequently, this study may not have captured smoking relapse in participants who did not smoke shortly before in-person visits, which took place weekly initially, and monthly later in the study. Other outcomes widely used in smoking cessation trials, including point-prevalence abstinence (a secondary outcome in this study) and prolonged abstinence, may better detect true rates of cessation than continuous abstinence ([@R5]). Finally, the calculated sample sizes needed for the study were based on efficacy estimates (46% for nicotine treatment and 30% for placebo) that were higher than the success rate actually observed in the study population. The 2 mg stratum was, therefore, limited by being underpowered, and the significance of the results may have been affected by enrollment of too few study subjects.

CONCLUSIONS
===========

In both the FAS and PPS populations, we found no statistical differences between the active and placebo groups in the 2 mg stratum, whereas in the 4 mg stratum, we observed a directionally significant improvement in smoking cessation rates compared with placebo in Chinese adult smokers with high nicotine dependence on the primary endpoint at 6 weeks. This finding was supported by statistically significant longer term smoking cessation rates at 12 and 24 weeks with the 4 mg nicotine mint lozenge compared with the placebo lozenge. Both 2 and 4 mg nicotine mint lozenges were generally well tolerated in this study based on the study safety data.

Unlike results from the FAS analysis, the post hoc analysis revealed significant between-treatment differences in smoking cessation rates at all time points in subjects in the 2 mg stratum with ≥2 previous quit attempts and suggests that the 2 mg nicotine mint lozenge may help Chinese adult smokers to quit and maintain the cessation for at least 6 months. This is potentially due to greater motivation to quit in subjects with more previous quit attempts. Further studies are needed to confirm these outcomes in Chinese adult smokers.
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